▟ Vinebot intrinsic value, daily

← back

ISRG Intuitive Surgical

healthcare · valued with opus medium conviction · deep-dived 2026-11-03

HOLD
Intrinsic value$256.64
Price (at call)$436.87
Margin of safety -41.3%
vs market (rating basis) -0.9%

A strong surgical-robotics franchise, but even generous drivers leave the price ahead of value.

The story

Intuitive Surgical is the dominant franchise in robotic-assisted surgery. Its moat comes from an installed base of more than 10,000 da Vinci systems, surgeon training lock-in, decades of clinical data and a razor/blade model where about 85% of revenue recurs from instruments, accessories and service. The company is in late high growth: procedure volume is still growing in the mid-teens as da Vinci 5 rolls out, Ion expands and the business pushes into general surgery and international markets. Competitors such as Medtronic Hugo and J&J Ottava are finally arriving, which will slowly squeeze pricing and share at the margin rather than break the franchise.

Procedure growth of 15-17% plus da Vinci 5 upgrades support about 15.5% growth in the first year, fading over a 12-year horizon that this durable moat justifies. Margins rise modestly from 32% to 35% through recurring revenue leverage, but competition and tariffs on instruments cap them below the old 38% peak. Sales-to-capital is set above the reported 0.65 because that figure is inflated by excess cash and by leased-system assets carried on the balance sheet; the marginal capital needed per dollar of new sales is lower.

Value drivers

Revenue growth (Y1)15.5%
Terminal growth4.0%
Forecast horizon12y
Target operating margin35.0%
Years to target margin5
Sales-to-capital1.20
Beta1.00
Failure probability0.5%
Cost of capital (WACC)9.4%
Terminal WACC9.4%

Valuation bridge

PV of explicit FCFF35.98B
PV of terminal value51.90B
Equity value90.67B
÷ shares → per share$256.64

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 13.37B 15.5% 32.8% 3.81B 1.50B 2.31B 2.12B
2 15.31B 14.5% 33.4% 4.43B 1.61B 2.82B 2.36B
3 17.36B 13.4% 33.9% 5.11B 1.71B 3.40B 2.60B
4 19.50B 12.4% 34.5% 5.84B 1.79B 4.05B 2.83B
5 21.71B 11.3% 35.0% 6.60B 1.84B 4.76B 3.04B
6 23.94B 10.3% 35.0% 7.28B 1.86B 5.42B 3.16B
7 26.15B 9.2% 35.0% 7.95B 1.84B 6.11B 3.26B
8 28.29B 8.2% 35.0% 8.60B 1.78B 6.82B 3.32B
9 30.31B 7.1% 35.0% 9.22B 1.68B 7.53B 3.36B
10 32.16B 6.1% 35.0% 9.78B 1.54B 8.24B 3.36B
11 33.78B 5.0% 35.0% 10.27B 1.35B 8.92B 3.32B
12 35.13B 4.0% 35.0% 10.68B 1.13B 9.55B 3.25B

Key risks

  • Medtronic Hugo, J&J Ottava and Chinese competitors compress system pricing and take share in cost-sensitive markets
  • Tariffs and hospital capital-budget pressure slow system placements and da Vinci 5 upgrade cycles
  • GLP-1 drugs reduce bariatric and some metabolic procedure volumes, and the valuation (about 13x sales) leaves no room for disappointment

Catalysts

  • da Vinci 5 full launch and new indications (cardiac, expanded general surgery) driving instrument use per procedure
  • International expansion (Japan, Europe, India) and Ion lung-biopsy adoption keeping procedure growth in the mid-teens

History

DatePriceIntrinsicMoSRating
2026-11-03$436.87 $256.64 -41.3% HOLD
2026-09-14$369.15 $90.07 -75.6% SELL
2026-07-24$332.02 $141.92 -57.3% HOLD
2026-06-23$403.18 $139.14 -65.5% SELL